
Cupid Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
Yes
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Cupid Limited aims to double its revenue in the next 2-3 years through development and expansion plans.
- FY22 revenue target is approximately Rs.150 crores, with a PAT of at least Rs.20 crores.
- FY23 revenue is expected to range between Rs.170-180 crores, driven partly by diagnostics sales, targeting a minimum 20% PAT margin.
- Capacity utilization is strong, with 98% for male condoms and 97% for female condoms.
- The company anticipates commercial production for IVD diagnostics starting Q4 FY22, expanding business verticals.
- US market entry is expected to generate a minimum $5 million in the first year with 30-40% profit margins; Cupid will be the second player after Veru Pharma.
- Marketing budget for female condoms in India may double, responding to slow domestic demand but significant growth potential.
- Tender opportunities in Tanzania, South Africa, and India are expected to add substantial volume.
See what Cupid management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no direct mention of any current or planned fundraising through equity in the transcript.
- On debt, it is noted that Cupid Limited has short-term borrowings of around Rs. 8 crores, down from Rs. 11-12 crores previously, primarily for working capital.
- There is no explicit discussion of new debt or equity fundraising plans in the call.
- The management mentioned being open to exploring excellent opportunities, but no specific fundraising initiatives were indicated.
- Overall, the transcript does not reveal any current or future fundraising through debt or equity being planned or underway.
See what Cupid management said on order book — free account, 30 seconds.
Capex plans
YesTrack Cupid — get its next earnings analysis in your feed
How does Cupid rank vs peers in Personal Products?
Pro featureHow does Cupid rank in Personal Products?
Compare Cupid against every Personal Products company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Cupid's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare (Q2 FY27)
Revenue (Standalone)** for H1 FY27: ₹5,786.31 Lakhs, up 21.43% YoY from ₹4,765.06 Lakhs in H1 FY26 . Key investor presentation takeaways from Anondita Medicare
- Gillette India (Q2 FY27)
Revenue from operations for the quarter ended 30th September 2026: ₹84,610 lakh (Page 3) . Key results statement takeaways from Gillette India Ltd's Q2 FY27 ear
- Honasa Consumer (Q2 FY27)
Younger brands, excluding The Derma Co., are growing healthily at 40%+ year-on-year, with the overall portfolio showing strong momentum across online and…
- Emami (Q2 FY27)
Volume growth for domestic business recorded 43% in Q2 and 26% on a like-to-like basis, indicating strong demand. Key concall takeaways from Emami Ltd's Q2…